PRTFDC1

Across TCGA pan-cancer cohorts, PRTFDC1 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated PRTFDC1 data layer compared with 25 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in esophageal carcinoma (ESCA), where higher PRTFDC1 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated PRTFDC1 expression acts as an unfavorable survival marker.

ESCA and PRAD are the cancer types where PRTFDC1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ESCA	DFS	Median	All	0.080	0.533	<.001	18	view →
PRAD	OS	Median	All	0.080	0.990	<.001	12	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

PRTFDC1–ESCA (DFS)

Open the ESCA breakdown →